Nasus Pharma Showcases NS002 as Potential EpiPen Alternative in KOL Event
Event summary
- Nasus Pharma to host virtual KOL event on June 10, 2026, featuring Michael S. Blaiss, MD, and Joel Brooks, DO, MPH.
- NS002, an intranasal epinephrine powder, aims to replace EpiPen as the standard treatment for anaphylaxis.
- Phase 2 data shows NS002 has faster and higher absorption than EpiPen.
- Event will discuss unmet needs in anaphylaxis treatment, particularly for pediatric patients.
The big picture
Nasus Pharma's NS002 represents a potential paradigm shift in anaphylaxis treatment, offering a needle-free alternative to EpiPen. The company's proprietary intranasal powder technology aims to leverage the nasal cavity's vascular network for rapid drug delivery, addressing a critical unmet need in pediatric care. The upcoming KOL event underscores the strategic importance of securing expert endorsements as the company prepares for potential regulatory milestones.
What we're watching
- Clinical Validation
- Whether NS002's Phase 2 data will translate into regulatory approval and market adoption.
- Market Disruption
- How NS002 could challenge EpiPen's dominance in the anaphylaxis treatment market.
- Pediatric Focus
- The pace at which Nasus Pharma can address the specific challenges faced by pediatric patients.
Related topics